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RNA interference with viral vectors that express short hairpin RNAs (shRNAs) has emerged as a powerful
tool for functional genomics and therapeutic purposes. However, little is known about shRNA in vivo process-
ing, accumulation, functional kinetics, and side effects related to shRNA saturation of the cellular gene
silencing machinery. Therefore, we constructed first-generation recombinant adenoviruses encoding different
shRNAs against murine ATP-binding cassette multidrug resistance protein 2 (Abcc2), which is involved in liver
transport of bilirubin to bile, and analyzed Abcc2 silencing kinetics. C57/BL6 mice injected with these viruses
showed significant impairment of Abcc2 function for up to 3 weeks, as reflected by increased serum bilirubin
levels. The lack of Abcc2 function correlated with a specific reduction of Abcc2 mRNA and with high levels of
processed shRNAs targeting Abcc2. Inhibition was lost at longer times postinfection, correlating with a
decrease in the accumulation of processed shRNAs. This finding suggests that a minimal amount of processed
shRNAs is required for efficient silencing in vivo. This system was also used to evaluate the effect of shRNA
expression on the saturation of silencing factors. Saturation of the cellular silencing processing machinery
alters the accumulation and functionality of endogenous microRNAs (miRNAs) and pre-miRNAs. However,
expression of functional exogenous shRNAs did not change the levels of endogenous miRNAs or their precur-
sors. In summary, this work shows that adenoviral vectors can deliver sufficient shRNAs to mediate inhibition
of gene expression without saturating the silencing machinery.
RNA interference (RNAi) is a sequence-specific posttran-
scriptional gene-silencing process originally described in Cae-
norhabditis elegans and plants (53). Subsequently, RNAi has
been described in many organisms where regulation of gene
expression is achieved by inducing DNA heterochromatiniza-
tion, mRNA cleavage, translation inhibition, or gene deletion
(29). It has been calculated that RNAi controls the expression
of 30% of human genes, some of which are involved in devel-
opmental timing, neuronal and hematopoietic cell fate, stem
cell division, and cell death and proliferation (35, 47). More-
over, a clear connection between cancer and RNAi has been
recently shown (8, 19, 38, 43, 46).
MicroRNAs (miRNAs) are short, 22-nucleotide (nt)-long,
noncoding RNAs that function as silencing effector molecules
(29). miRNAs are transcribed as long primary transcripts
(160 nt long or longer, called pri-miRNAs) that undergo a
sequential maturation process. First, pri-miRNAs are cleaved
in the nucleus by an RNase III called Drosha into imperfectly
pairing stem-loop precursors of 70 nt called pre-miRNAs
(29, 34). The pre-miRNAs are then exported to the cytoplasm
by a Ran-GTP-dependent process mediated by exportin 5
(Exp-5) (5, 16, 30, 40, 59). Once in the cytoplasm, Dicer processes
pre-miRNAs, rendering mature double-stranded miRNAs (see
Fig. 2A) that interact with the RNA-induced silencing complex
(RISC) (4, 29, 53). The antisense strand of the miRNA must be
incorporated into RISC to mediate sequence-specific mRNA reg-
ulation (53).
RNAi-based technology is a powerful tool for functional
genomic studies and constitutes a promising source for new
therapeutic approaches (17). These goals can be achieved
by molecules similar to pre-miRNAs and miRNAs called
short hairpin RNAs (shRNAs) and small interfering RNAs
(siRNAs), respectively. shRNAs are similar in structure to
pre-miRNAs and mature following the same Exp-5/Dicer path-
way into siRNAs (16, 30, 31, 59). siRNAs are 21-nt-long
RNA duplexes that interact with RISC to mediate gene silenc-
ing similarly to what has been described above for miRNAs
(53). However, pairing between siRNAs and target sequences
is generally designed to be perfect, activating a RISC-mediated
cleavage of the target mRNA, while in most cases the func-
tional binding size between the miRNA and the target mRNA
is only 6 to 8 nt, inducing a RISC-mediated inhibition of
mRNA translation or a decrease in mRNA stability (53).
Delivery of siRNAs and shRNAs into mammalian cells has
been achieved by several means. In cell culture, the simplest
method is transfection of chemically synthesized siRNAs or
plasmids expressing shRNAs (6, 11). In vivo silencing has been
obtained by administration of synthetic siRNAs or by viral
vectors expressing shRNAs such as lentiviruses, retroviruses,
adeno-associated viruses (AAV), or adenoviruses (21, 36, 42,
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49, 52, 55, 57). Viral vectors offer several advantages for de-
livery of shRNAs, including longer expressions and better
transduction efficiencies than siRNA administration (21, 57).
Several reports have described inhibition of liver messengers
with siRNAs and shRNAs, making the liver a suitable target
organ for RNAi approaches (36, 52, 55, 57). Adenoviruses are
excellent vectors for liver gene delivery because of their high
liver tropism and infection efficiency that allows massive he-
patic transduction with a short-term expression profile (51, 56).
However, little is known about adenovirus-delivered kinetics of
functional shRNAs. Also, RNAi amplification or cell-to-cell
transmission, as happens in C. elegans, has never been evalu-
ated in the liver. Finally, undesirable side effects of shRNA
expression in the liver have not been studied in detail. Side
effects related to shRNA delivery could be associated with
off-target gene silencing, induction of interferon response, or
saturation of the endogenous RNAi machinery (23, 24, 58).
Several reports have shown that the endogenous RNAi ma-
chinery is limiting. Thus, Exp-5 has been saturated in tissue
culture cells expressing high levels of shRNAs and overexpres-
sion of Exp-5 has been shown to increase RNAi efficiency (58).
Saturation of RISC has also been demonstrated in tissue cul-
ture cells (23). Also, Dicer function has been inhibited in the
presence of double-stranded RNA-binding proteins or by in-
cubation with double-stranded RNAs, such as virus-associated
(VA) RNAs (2, 37, 39). VA RNAs are 160-nt-long double-
stranded RNA molecules expressed in adenovirus-infected
cells (41). Thus, adenovirus expressing shRNAs could saturate
the cellular silencing machinery by expression of exogenous
shRNAs and VA RNAs, as well as expression of adenovirus
miRNAs, as has been recently described (2, 3, 48). Also, wild-
type adenovirus (AdWT) infection has been shown to inacti-
vate RISC in tissue culture (2). Inhibition of the silencing
machinery would decrease the level and functionality of en-
dogenous miRNAs and therefore alter the expression of target
cellular genes. This altered expression in the cell could lead to
toxicity by different mechanisms. In fact, the expression of
miRNAs is lower in cancer cells and it has been suggested that
reduced miRNA expression leads to a cancer-specific block of
expression that interferes with the normal development of the
cells (38).
To study adenovirus-delivered shRNA kinetics and cellular
effects, we constructed first-generation recombinant adenovi-
ruses encoding different shRNAs to silence the murine ATP-
binding cassette subfamily C member 2 multidrug resistance
protein 2 (Abcc2/MRP2/cMOAT) (AdshAbcc2). Abcc2 is a
liver export pump located in the canalicular membrane of
hepatocytes responsible for secretion of conjugated bilirubin to
bile (7, 27, 28). Mutations in the gene for Abcc2 are respon-
sible for Dubin-Johnson syndrome, a hereditary disease char-
acterized by conjugated hyperbilirubinemia (25, 26, 32, 54).
We monitored Abcc2 silencing after intravenous administra-
tion of AdshAbcc2 in C57/BL6 mice for up to 150 days. By
quantitative reverse transcription (RT)-PCR and measure-
ment of serum bilirubin accumulation, we demonstrated Abcc2
knockdown and functional inhibition for 3 weeks. Abcc2 inhi-
bition correlated with higher levels of processed antisense
shRNAs targeting Abcc2, while lower nonfunctional accumu-
lation was detected for up to 150 days. Moreover, adenovirus-
mediated expression of functional shRNAs did not affect the
accumulation or processing of endogenous miRNAs such as
let-7, miR16, or miR21. These results indicate that adenovirus
vectors can be used to express a sufficient level of shRNAs in
mouse liver capable of silencing target genes without inhibition
of the cellular RNAi machinery.
MATERIALS AND METHODS
Plasmids. Enhanced green fluorescent protein (GFP) cDNA was digested with
NotI, filled with Klenow, excised with PstI from pEGFP (Promega), and cloned
into PstI-SmaI-digested pAdLox (kind gift from S. Hardy) downstream of the
cytomegalovirus promoter (18, 45) to generate pAdLoxGFP. We used pSuper
(kindly given by R. Agami) to construct the plasmids that express shRNAs
(6). Proper oligonucleotide sequences (Sigma) were cloned into the BglII and
HindIII sites of pSuper to obtain plasmids expressing shAbcc2a and shAbcc2b
(Table 1; Fig. 1A). Similarly, oligonucleotides containing Abcc2-unrelated se-
quences were used to obtain a plasmid expressing shMock. These plasmids were
digested with EcoRI and XhoI, and fragments containing shRNA sequences
downstream of the H1 promoter were cloned in the orientation opposite to that
of the adenovirus E1 gene into XhoI-EcoRI-opened pAdlox. This generated
pAdLoxshAbcc2a, pAdLoxshAbcc2b, and pAdLoxshMock. Positive clones were
verified by DNA sequencing (ABI Prism 310 genetic analyzer from Perkin-
Elmer).
Cell lines. Human embryonic kidney 293 cells (adenovirus E1 transformed)
and murine hepatoma cell line Hepa 1-6 were obtained from the American Type
Culture Collection. The CRE8 selective cell line was kindly provided by S.
Hardy. All cell lines were cultured in Dulbecco modified Eagle medium supple-
mented with 10% fetal calf serum, 2 mM L-glutamine, and 100 U/ml streptomy-
cin-penicillin. Cell lines were cultured at 37°C in a 5% CO2 atmosphere. All cell
culture reagents were obtained from GIBCO BRL/Life Technologies.
Adenovirus construction and cell infection. Recombinant adenoviruses ex-
pressing GFP (AdGFP) and mock shRNA or shRNAs against murine Abcc2
(AdshAbcc2a and AdshAbcc2b) were constructed with the Cre-lox recombina-
tion system (18, 45). Briefly, CRE8 cells were cotransfected by using calcium
phosphate with 5 DNA and SfiI-predigested pAdLoxGFP, pAdLoxshMock,
pAdLoxshAbcc2a, or pAdLoxshAbcc2b. After 7 to 10 days, lysates from cotrans-
fected cells were used to infect CRE8 cells in order to remove the 5 helper
virus contamination. Four passages were performed to ensure efficient 5 re-
moval (data not shown). Lysates from the last passages were used to infect 293
cells to amplify adenoviruses. Packaged viral DNA was purified as previously
described (18) and analyzed in agarose gels after BsaBI digestion (Fig. 1B).
These adenoviruses and an adenovirus that expresses luciferase (AdLuc; kindly
provided by J. Wilson) were amplified in 293 cells, purified by double cesium
chloride gradient ultracentrifugation, and desalted by dialysis overnight at 4°C
against phosphate-buffered saline, pH 7.2 (45). Adenovirus infective unit titers
were determined by limiting dilution. Hepa 1-6 cells were infected with adeno-
virus as previously described, with a multiplicity of infection (MOI) of 600 (45).
This MOI was sufficient to infect 99% of the cells as determined by fluorescence-
activated cell sorter analysis (data not shown).
Animal treatments and serum analysis. Five- to 6-week-old C57/BL6 mice
(Harlan) received 2  109 infective units of adenovirus in 200 l of saline by
intravenous injection into the tail vein. Blood and liver samples were collected at
the indicated times postinfection. Mouse blood samples were drawn from the
retroorbital sinus and immediately stored in darkness. After 30 to 60 min of
incubation at room temperature, samples were centrifuged at 10,000 rpm in a
table microcentrifuge and serum samples were stored at 20°C. Bilirubin levels
were determined with a total bilirubin kit (ABX Diagnostics) in a Hitachi auto-
analyzer (Roche Diagnostics) by following the supplier’s recommendations.
When indicated, animals received an intravenous injection in the tail vein of 100
l of 100 mM NaCl and 50 mM Na2CO3 with 10 mg/kg bilirubin (Sigma) 40 min
before blood was drawn (22). All experiments with animals were performed by
following guidelines from the institutional ethical commission.
Protein analysis. For liver histological analysis, mice were intravenously in-
jected by the tail vein with 150 l of AdGFP containing 2  109 or 109 infective
units. At 7 and 24 days after adenovirus administration, the animals were sacri-
ficed and their livers were excised and fixed overnight in 3.7% paraformaldehyde
in CSK buffer (14). Samples were then embedded in Tissue-Tek OCT (Sakura),
snap-frozen in liquid nitrogen, and stored at 80°C. For GFP analysis, samples
were sliced, dried overnight at room temperature in the dark, mounted with
Vectashield 4,6-diamidino-2-phenylindole (DAPI) solution (Vector Laborato-
ries), and analyzed with a Nikon fluorescence microscope.
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Preparation and analysis of RNA. Total RNA from Hepa 1-6 cells was purified
by the guanidinium method as previously described (9). Frozen livers were
homogenized in denaturing solution (9) with an Ultraturrax (Ika-Werke) at 4°C,
and total RNA was purified by the guanidinium method.
Total RNA was repurified with an RNeasy Minikit (QIAGEN) for real-time
quantitative RT-PCR. The RT reaction was done with Moloney murine leukemia
virus reverse transcriptase (Promega) for 1 h at 37°C. Real-time quantitative PCR
was performed with a LightCycler system (Roche Diagnostics) with LightCycler
Faststart Master DNA SYBR green I (Roche) by following the supplier’s in-
structions. Sequences of forward and reverse primers for Abcc2 mRNA and
murine actin mRNA quantification by LightCycler RT-PCR are indicated in
Table 1. The amplification program consisted of 1 cycle of 95°C for 1 min,
TABLE 1. Oligonucleotides used in this study
Name Sequence Usea
pSAbcc2AS GATCCCCGATACTGGACAAGCCACAATTCAAGAG
ATTGTGGCTTGTCCAGTATCTTTTTGGAAA
Cloning of pSUPERshAbcc2a
pSAbcc2aAS AGCTTTTCCAAAAAGATACTGGACAAGCCACAAT
CTCTTGAATTGTGGCTTGTCCAGTATCGGG
Cloning of pSUPERshAbcc2a
pSAbcc2bS GATCCCCTTCTCTACCTATGCACTTGTTCAAGAGA
CAAGTGCATAGGTAGAGAATTTTTGGAAA
Cloning of pSUPERshAbcc2b
pSAbcc2bAS AGCTTTTCCAAAAATTCTCTACCTATGCACTTGTCT
CTTGAACAAGTGCATAGGTAGAGAAGGG
Cloning of pSUPERshAbcc2b
Abcc2S197 CCAAGCAGGTGTTCGTTGTGT qPCR of Abcc2 mRNA
Abcc2AS628 TGTCATACCAACTAAACGTAACGC qPCR of Abcc2 mRNA
mActin5 ACTGCGCTTCTTGCCGC qPCR of murine actin mRNA
mActin3 CATGACGCCCTGGTGTC qPCR of murine actin mRNA
asAbcc2a AAGATACTGGACAAGCC PE of shAbcc2a, Northern blotting
asAbcc2b AATTCTCTACCTATGCA PE of shAbcc2b, Northern blotting
Let-7 AAAACTATACAACCTACTAC PE of Let-7, Northern blotting
miR16 AACGCCAATATTTACGTGC PE of miR16, Northern blotting
miR21 AGTCAACATCAGTCTGATAA PE of miR21, Northern blotting
pre-miR16 AGAATCTTAACGCCAATATT PE of pre-miR16, Northern blotting
pre-miR21 GATTCAACAGTCAACATCAG PE of pre-miR21, Northern blotting
U6 snRNA TGCTAATCTTCTCTGTATCGT PE of U6 snRNA, Northern blotting
Let-7Arrestor UGAGGUAGUAGACGCAG Invader quantification of Let-7
Let-7Probe CCGTCGCTGCGTCTACTACCTCAGGCUUCGGCC Invader quantification of Let-7
Let-7Invader GGCUUCGGCCAACTATACAACT Invader quantification of Let-7
miR21Arrestor UAGCUUAUCAGAGUGCGC Invader quantification of miR21
miR21Probe AACGAGGCGCACTCTGATAAGCTAGGCUUCGGCC Invader quantification of miR21
miR21Invader GGCUUCGGCCTCAACATCAGG Invader quantification of miR21
a qPCR, quantitative PCR; PE, primer extension.
FIG. 1. Schematic representation of shRNAs targeting Abcc2 mRNA (Abcc2 shRNAs) and adenovirus expressing Abcc2 shRNAs (AdshAbcc2).
(A) Sequence and structure of Abcc2 shRNAs. Two constructs were designed that express shRNAs targeting Abcc2 mRNA sequences. The linear
sequence and the predicted folded hairpin are shown for each Abcc2 shRNA. Transcription initiation is indicated by an arrow. Sense and antisense
sequences are shown in bold. (B) A first-generation adenovirus genome with E1 and E3 deleted (black boxes) is shown, and the relative positions
of BsaBI restriction sites are indicated. The 5 end of the genome is highlighted above, including the 5 internal terminal repeat (ITR), the
packaging signal (), the loxP site, and, in the opposite direction, the H1 promoter driving the expression of the shRNA formed by sense (s) and
antisense (as) sequences separated by a loop.
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followed by 40 cycles of 95°C for 20 s, 59°C (Abcc2) or 64°C (actin) for 5 s, and
72°C for 20 s (Abcc2) or 15 s (actin). Melting curve analysis was performed at
83°C (Abcc2) or 91°C (actin). The average of triplicate data of each sample was
used to calculate the relative change in gene expression after normalization to
actin mRNA.
Primer extension analysis of shRNAs, miRNAs, and U6 snRNA was per-
formed with total RNA isolated from Hepa 1-6 cells or from homogenized frozen
liver extracts, as previously described (3, 12). Primer sequences are shown in
Table 1. Primer extension conditions were set up to work in the linear range.
Northern blot assays were done as previously described, with oligonucleotides in
Table 1 (3, 13). Invader quantification of let-7 and miR21 was done by following
the recommendations of the supplier (Third Wave) (1). U6 snRNA quantifica-
tion was done in the same experiments as an internal control. The oligonucleo-
tides used are listed in Table 1.
Statistical analysis. Results are shown as the arithmetic mean 	 the standard
error of the mean. Statistical comparisons were made by analysis of variance.
Differences were deemed significant for a real alpha of 0.05. All statistical
analyses were carried out with SPSS v11.0 (SPSS, Inc.).
RESULTS
Adenovirus-mediated Abcc2 silencing in murine hepatoma
cells. Two different shRNAs, targeting Abcc2 mRNA nt 265
to 283 and 311 to 329 (Abcc2a and -b shRNAs, respec-
tively), were designed according to recommended properties
(10) and mFold-predicted secondary structure for Abcc2
mRNA (60) (data not shown; Fig. 1A). Abcc2 shRNA se-
quences were cloned into pSuper (6) and then inserted into
the genome of recombinant adenovirus defective in the E1
and E3 early genes (18). This generated adenovirus expressing
shRNAs against Abcc2 mRNA (AdshAbcc2a and -b) tran-
scribed from the H1 promoter in the direction opposite to that
of the adenovirus 5 internal terminal repeat (Fig. 1B). A
similar adenovirus was generated which expresses an shRNA
unrelated to Abcc2 (AdshMock).
In AdshAbcc2-infected cells, the corresponding shRNA
should be expressed and processed by Dicer into siRNAs (Fig.
2A). However, only one of the strands of a single siRNA will
remain attached to the RISC complex (53). Target Abcc2
mRNA expression should be inhibited if enough RISC com-
plexes incorporate the antisense strand of Abcc2 siRNA. Thus,
the presence of this antisense strand was analyzed by primer
extension of total RNA isolated from Hepa 1-6 cells infected
with the AdshAbcc2 viruses at 600 infective units/cell. This
MOI guarantees that all cells have been infected (data not
shown). As shown in Fig. 2B, a 21-nt band was detected by
primer extension with a specific oligonucleotide that hybridizes
to the antisense strand of Abcc2a siRNA (oligonucleotide
asAbcc2a, Fig. 2A and Table 1). This band was specific for
AdshAbcc2a-infected cells (Fig. 2B, lane 3), as it was not
detected in mock-infected cells or in cells infected with
AdshAbcc2b, AdshMock, or AdGFP (Fig. 2B, lanes 1 and 2
and lanes 4 and 5). Similar experiments confirmed the pres-
ence of the antisense strand of Abcc2b siRNA and the sense
strand of Abcc2a and Abcc2b siRNAs (data not shown). How-
ever, we were unable to detect unprocessed Abcc2 shRNAs by
Northern blot assay or primer extension, indicating efficient
processing by Dicer (data not shown).
The detection of the antisense siRNAs correlated with a
decrease in Abcc2 mRNA. The levels of Abcc2 mRNA were
quantified by LightCycler RT-PCR of RNA isolated at 72 h
postinfection from Hepa 1-6 cells mock infected or infected
FIG. 2. Hepa 1-6 cells infected with AdshAbcc2 show decreased Abcc2 mRNA levels. (A) Schematic representation of shRNA processing
detected by primer extension. An shRNA targeting Abcc2 mRNA (Abcc2a shRNA) can be processed by Dicer to an siRNA (Abcc2a siRNA). The
accumulation of the antisense strand of Abcc2a siRNA can be detected by hybridization or extension from oligonucleotide asAbcc2a. (B) Detection
of the antisense strand of Abcc2a siRNA in AdshAbcc2a-infected cells. Buffer only (Oligo) or RNA isolated from Hepa 1-6 cells (Mock) or cells
infected for 72 h with the AdGFP, AdshMock, or AdshAbcc2 virus was subjected to primer extension with oligonucleotide asAbcc2a. The positions
of the oligonucleotide and of the antisense strand of Abcc2a siRNA (asAbcc2a siRNA) are indicated to the left. The position of the 20-bp marker
is indicated to the right. (C) Abcc2 mRNA levels are decreased in AdshAbcc2-infected cells. Total RNA described in panel B was used to quantify
Abcc2 and actin mRNA by LightCycler RT-PCR. The values shown are percentages of Abcc2 and actin mRNA expression compared to those of
mock-infected cells. Error bars indicate standard deviations obtained after quantification of three different experiments.
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with AdGFP or the AdshAbcc2 viruses. Abcc2 mRNA levels of
cells infected with AdshAbcc2a or AdshAbcc2b were 15% and
31%, respectively, of the values observed in AdGFP- or mock-
infected cells (Fig. 2C). However, similar amounts of the non-
targeted actin mRNA were found in all cases. This ensures
integrity of the RNA samples and specificity of Abcc2 mRNA
inhibition.
Intravenous administration of the AdshAbcc2 viruses to
mice causes hyperbilirubinemia and a decrease in Abcc2 mRNA.
Adenoviruses have been proven to be valuable gene delivery
vectors in vivo with special tropism for the liver (51). To ana-
lyze if AdshAbcc2 viruses could inhibit Abcc2 mRNA expres-
sion in mouse liver, we first set up conditions to infect most
liver cells. Thus, increasing amounts of AdGFP were adminis-
tered by the tail vein to three to five C57/BL6 mice per group
(data not shown). Animals were sacrificed 7 to 24 days postin-
fection (dpi) for histological analysis of liver samples by fluo-
rescence microscopy. Under our experimental conditions, 2 
109 infective units/mouse is the minimal dose of AdGFP
needed to detect GFP expression in more than 95% of the
hepatocytes after 7 dpi (Fig. 3A). According to the adenovirus
short-term expression properties, less than 5% of the hepato-
cytes expressed GFP 24 days after AdGFP administration (Fig.
3A) (56). In agreement with these results, a strong light emis-
sion signal was observed with a charge-coupled device camera
in the liver area of mice injected with AdLuc at 7 dpi but not
at 24 dpi (data not shown). These experiments also showed
that adenovirus transgene expression increases up to 7 dpi with
the vector in C57/BL6 mice (data not shown; 56).
Thus, five to seven C57/BL6 mice per group were injected
intravenously with 2  109 infective units of AdLuc,
AdshAbcc2a, AdshAbcc2b, or AdshMock. A group of mice
receiving the vehicle alone (saline) was also included as a
negative control. At 7 dpi, the animals were sacrificed for
collection of serum and liver samples. RNA isolated from liver
extracts was analyzed by primer extension or Northern blot
assay. As was observed in Hepa 1-6 cells (Fig. 2B), a 21-nt
specific band was extended from oligonucleotide asAbcc2a
FIG. 3. AdshAbcc2 administration in mice affects Abcc2 functionality. (A) Dose required to infect more than 95% of hepatocytes. Mice were
mock infected or infected with 2  109 infective units of AdGFP/mouse, and liver samples were processed at 7 or 24 dpi. Histological analysis of
liver samples stained with DAPI (blue) was visualized in a fluorescence microscope. GFP expression is shown in green. (B, C) The antisense strand
of Abcc2 siRNAs is detected in AdshAbcc2-infected animals. Mice were mock infected or infected with AdLuc or AdshMock as controls or
infected with AdshAbcc2a or AdshAbcc2b. At 7 days posttreatment, serum and liver samples were analyzed. Buffer only (oligo) or total liver RNA
was analyzed by primer extension with oligonucleotide asAbcc2a (B) or by Northern blot assay with oligonucleotide asAbcc2b (C). The position
of the antisense strand of Abcc2a siRNA or Abcc2b siRNA (asAbcc2 siRNA) is indicated to the left. The position of the 20-bp marker is indicated
to the right. (D) Abcc2 mRNA levels are decreased in AdshAbcc2-infected animals. Total RNA described in panel B was used to quantify Abcc2
and actin mRNAs by LightCycler RT-PCR. Results were plotted as indicated in Fig. 2C. (E) AdshAbcc2 administration to mice causes
hyperbilirubinemia. Mice described in panel B were injected with synthetic bilirubin, and 40 min later, serum samples were collected to quantify
bilirubin levels. Error bars indicate standard deviations obtained with five to seven animals.
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(Table 1) incubated with liver RNA from AdshAbcc2a-in-
fected animals (Fig. 3B, lanes 4 and 5). A similar band was
observed when RNA from AdshAbcc2b-infected animals was
hybridized with oligonucleotide asAbcc2b (Table 1; Fig. 3C,
lanes 3 and 4). These bands were specific since they were not
detected in mock-infected animals or in animals infected with
the other adenoviruses tested (Fig. 3B, lanes 2 and 3 and lanes
6 to 9, and C, lanes 1 and 2). The presence of the antisense
strand of Abcc2 siRNAs correlated with a decrease in Abcc2
mRNA accumulation. Quantification of Abcc2 mRNA levels
by quantitative RT-PCR from liver RNA samples showed that
Abcc2 mRNA amounts were 5% and 12% of the levels of the
control groups in AdshAbcc2a- and AdshAbcc2b-receiving
mice, respectively (Fig. 3D). This decrease was specific, as
similar levels of the nontargeted actin mRNA were found in all
cases (Fig. 3D).
Abcc2 transports serum bilirubin to bile in hepatocytes. Al-
terations in the Abcc2 gene are the cause of Dubin-Johnson
syndrome, which is characterized by hyperbilirubinemia and
jaundice (7, 25, 26, 32). It could then be expected that Abcc2
mRNA silencing would cause a decrease in Abcc2 expression,
reduced transport of bilirubin to bile, and hyperbilirubinemia.
To assess whether AdshAbcc2a and AdshAbcc2b lead to
Abcc2 functional inhibition in vivo, bilirubin was measured in
serum samples collected from three to five mice per group in-
fected as described above. We observed a significant increase in
serum bilirubin in mice receiving AdshAbcc2a or AdshAbcc2b
(0.90 	 0.66 mg/dl) compared to control animals (0.11 	 0.05
mg/dl). Serum bilirubin forms as a by-product of erythrocyte
turnover, which, under normal conditions, does not saturate
the machinery that transports bilirubin to bile. To study the
effect of AdshAbcc2 viruses with saturating bilirubin, five to
seven mice per group infected as described above received 10
mg/kg of synthetic bilirubin intravenously and blood was col-
lected 40 min later (22). After this time, synthetic bilirubin was
completely cleared in control mice, while mice injected with
AdshAbcc2a or AdshAbcc2b showed marked hyperbiliru-
binemia (Fig. 3E).
AdshAbcc2 liver transduction impairs bilirubin clearance for
up to 3 weeks. Once we detected Abcc2 functional inhibition and
bilirubin clearance impairment 7 days after AdshAbcc2 injection,
we analyzed in vivo Abcc2 silencing kinetics following AdshAbcc2
administration. Five to seven C57/BL6 mice per group were mock
injected or injected with 2 109 infective units of AdshAbcc2a or
with AdshMock or AdLuc as negative controls. Liver and serum
samples were collected on different days postinfection. Serum
bilirubin was quantified 40 min after synthetic bilirubin injection
on days 1, 3, 5, 9, 19, 24, and 150 post virus administration. We
found normal levels of serum bilirubin in all animals at 1 and 3
dpi (Fig. 4A and data not shown). This was expected since ex-
pression from adenovirus is observed from 48 h posttransduction
(56) and some time should be required from Abcc2 mRNA deg-
radation to functional impairment of Abcc2 protein. Remarkably,
we detected high bilirubin values from day 5 until day 19 postin-
jection of AdshAbcc2a (Fig. 4A). In these animals, the increase in
bilirubin was maximal at 9 dpi and was no longer significant at day
FIG. 3—Continued.
VOL. 80, 2006 IN VIVO EFFECT OF ADENOVIRUS-DELIVERED shRNAs 12241
 o
n
 August 28, 2012 by Universidad de Navarra
http://jvi.asm.org/
D
ow
nloaded from
 
24 after AdshAbcc2a administration (Fig. 4A). In control animals
or in all animals analyzed at 150 dpi, serum bilirubin showed
values similar to baseline levels (Fig. 4A and data not shown).
RNA was isolated from liver samples taken from the animals
described above at 7, 12, 24, and 150 dpi. Liver RNA was also
isolated at 7 dpi from three mice transduced with AdshAbcc2b.
Abcc2 mRNA levels quantified by real-time RT-PCR showed
a significant reduction in mice infected with AdshAbcc2b or
with AdshAbcc2a for 7 or 12 days (Fig. 4B). This result is in
agreement with the functional inhibition of Abcc2 shown
FIG. 4. AdshAbcc2 liver transduction affects Abcc2 functionality
for up to 3 weeks. (A) AdshAbcc2-infected animals show hyperbiliru-
binemia for 19 days. Mice were mock injected or injected with 2  109
infective units of AdshMock or AdLuc as negative controls or with
AdshAbcc2a. Bilirubin was quantified in serum samples collected on
days 3, 5, 9, 15, 19, and 24 post virus administration and 40 min after
synthetic bilirubin injection. Error bars indicate standard deviations.
Asterisks highlight significant differences. (B) Abcc2 mRNA is de-
creased in AdshAbcc2-treated animals for up to 12 days. Liver RNA
was isolated from animals treated as described in panel A, at 7, 12,
24, and 150 dpi. Liver RNA was also isolated from animals trans-
duced with AdshAbcc2b for 7 days. Liver RNA was used to quantify
Abcc2 mRNA by LightCycler RT-PCR. Results are plotted as in-
dicated in Fig. 2C. (C) Antisense siRNAs against Abcc2 mRNA
were detected at 150 dpi with AdshAbcc2a. Liver RNA described in
panel B or buffer (oligo) was analyzed by primer extension with
oligonucleotide Abcc2aAS (top). Some of the samples were also
analyzed by Northern blot assay hybridized to oligonucleotide
asAbcc2a (bottom). The positions of the oligonucleotide and the
antisense Abcc2a siRNA (asAbcc2a siRNA) are indicated to the
left. The position of the 20-bp marker is indicated to the right.
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above. Control animals and all animals analyzed after 24 or 150
dpi showed normal levels of Abcc2 mRNA (Fig. 4B and data
not shown). Also, the inhibition was specific for Abcc2 mRNA,
as normal levels of actin mRNA were found in all cases.
The accumulation of small RNAs against Abcc2 mRNA was
analyzed in the liver RNA samples described above by North-
ern blot assay and primer extension with oligonucleotide
asAbcc2a. Both techniques detected high levels of antisense
Abcc2a siRNAs in mice transduced with AdshAbcc2a at 7 and
12 dpi (Fig. 4C, lanes 1 to 5). Thus, the decrease in Abcc2
mRNA and the impairment of bilirubin clearance correlated
with a strong accumulation of siRNAs against Abcc2 mRNA.
Small RNAs were not detected with oligonucleotide asAbcc2a
in control samples (Fig. 4C, lanes 10 to 14). Interestingly, we
were able to detect a weak signal corresponding to antisense
Abcc2a siRNA at day 24, and even day 150, postinfection (Fig.
4C, lanes 6 to 9). However, these levels of small RNA were not
sufficient to silence Abcc2 mRNA since bilirubin clearance and
Abcc2 mRNA values were similar to those of controls (Fig. 4A
and B).
Expression of functional shRNAs does not affect processing
or accumulation of endogenous liver miRNAs. Because
shRNAs and miRNAs share the same processing and nuclear
export machinery (30, 31), we explored whether functional
expression of shRNAs in the liver could modify endogenous
miRNA processing or accumulation. Thus, miRNAs were
quantified in liver RNA samples isolated from mice mock
transduced or transduced with 2 109 infective units of AdLuc
or AdshAbcc2a at 7, 12, 24, or 150 dpi. These RNAs were
normalized to U6 snRNA, and accumulation of several endog-
enous miRNAs was analyzed. Out of seven cellular miRNAs
chosen, only let-7, miR16, miR21, and liver-specific miR122
were expressed to detectable amounts in mouse liver cells (33).
Accumulation of these miRNAs was analyzed by primer ex-
tension and Northern blot assay with specific oligonucleotides
(Fig. 5A; Table 1; data not shown). Quantification of the re-
sults obtained with primer extensions and Northern blot assays
indicated variability in the amount of endogenous miRNAs in
different animals. However, statistical analysis revealed non-
significant differences between liver extracts from AdLuc- or
mock-treated mice and AdshAbcc2a-injected mice (data not
shown). Also, there were no differences among controls and
mice treated with AdshAbcc2b and analyzed at 7, 12, or 24
days posttreatment (data not shown). The Invader technique
to quantify endogenous miRNAs was also used to reduce the
mouse-to-mouse variability observed by Northern blot assay or
primer extension (1). When quantification of let-7 or miR21
was carried out with Invader assays, similar results were ob-
tained but with a lower variability. No differences were ob-
served between controls or AdshAbcc2a-infected animals an-
alyzed at 7, 12, 24, or 150 days posttreatment (Fig. 5B and C).
Competition of functional shRNAs for the silencing process-
ing machinery could still induce the accumulation of miRNA
precursors (pre-miRNAs). Thus, a blockade of Exp-5 or Dicer
should alter the localization and accumulation of pre-miRNAs.
Therefore, accumulation of pre-miR16 and pre-miR21 was
analyzed by primer extension (Fig. 5D) and Northern blot
assay (data not shown) with specific antisense oligonucleotides
(Table 1). Again, quantification of pre-miR16 or pre-miR21
did not reveal significant differences between liver extracts
from control mice or AdshAbcc2a-transduced mice analyzed at
7, 12, 24, or 150 days posttreatment (data not shown).
DISCUSSION
One of the major obstacles to using siRNAs in vivo is their
efficient delivery into the target tissue or organ. The experience
accumulated in recent years in the gene therapy field has led to
the optimization of several viruses as gene delivery vectors.
Thus, viral vectors expressing shRNAs have proven to be valu-
able vehicles to achieve RNAi (21, 49, 55, 57). However, de-
tailed studies analyzing the kinetics of inhibition or the side
effects related to functional shRNA expression in vivo have not
been carried out. To address these questions, we have chosen
first-generation adenoviruses that silence the hepatocellular
Abcc2 transporter in mouse liver. With these vectors, we were
able to induce Abcc2 silencing in tissue cultured liver cells (Fig.
2C) and in murine liver (Fig. 3D and 4B), whereas other
approaches such as hydrodynamic administration of plasmid
coding for shAbcc2 had failed (data not shown).
AdshAbcc2 caused Abcc2 silencing from day 5 up to day 19
after vector administration (Fig. 4A). As Abcc2 transports
bilirubin into bile, silencing of Abcc2 was detected by hyper-
bilirubinemia (Fig. 3D and 4A). Hyperbilirubinemia is also
detected in patients with Dubin-Johnson syndrome, in
whom Abcc2 function is impaired (25, 26, 32, 54). Thus, our
AdshAbcc2 adenoviruses could be administered in mice to
generate transient knockdowns that could serve as mouse
models for Dubin-Johnson syndrome and for the study of the
pathophysiological consequences derived from Abcc2 dysfunc-
tion. Moreover, Abcc2, among other ATP-binding cassette
transporters, has important clinical implications since it is re-
sponsible for excretion of drugs and xenotoxins and for resis-
tance to multiple chemotherapeutic agents (20). Thus, our
system could enable a better definition of the implication of
this transporter in specific metabolic functions and may serve
to enhance the sensitivity of liver cancer cells to chemothera-
peutic agents.
Impairment of Abcc2 function correlates with a decrease in
liver Abcc2 mRNA as detected by RT-PCR (Fig. 3D and 4B).
Abcc2 mRNA levels decreased at days 7 and 12 after adeno-
virus injection but were back to normal at day 24, when the
increase in blood bilirubin was not significant (Fig. 4A and B).
This kinetics of inhibition follows a classical short-term expres-
sion pattern of first-generation adenoviral vectors (Fig. 3A).
Silencing is mediated by the antisense strand of processed
shRNAs. These antisense small RNA mediators were detected
by Northern blot assay or primer extension up to 150 days after
AdshAbcc2 administration in mice (Fig. 4C). This suggests the
existence of an siRNA reservoir and/or the persistence of few
copies of adenovirus genomes in liver cells. We favor the latter
hypothesis since we were able to detect viral genomes by quan-
titative PCR in DNA extracts from murine livers 150 days after
injection with AdshAbcc2a (data not shown). However, the
low levels of antisense Abcc2 siRNA detected 24 or 150 days
post AdshAbcc2 administration were not sufficient to silence
Abcc2 (Fig. 4). Only the levels detected at days 7 and 12 were
efficient inhibitors of Abcc2 (Fig. 4). These results indicate that
there is a threshold amount of siRNAs required for efficient
silencing. Also, these functional levels need to be expressed in
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FIG. 5. Expression of functional shRNAs does not affect processing or accumulation of endogenous liver miRNAs. (A) Accumulation of
miRNAs is not altered in AdshAbcc2-infected cells as detected by primer extension. Buffer (oligo) or liver RNA described in Fig. 5 was analyzed
by primer extension with oligonucleotides that hybridize to let-7, miR16, miR21, or U6 snRNA (as a loading control). (B, C) let-7 (B) and miR21
(C) accumulation is not altered in AdshAbcc2-infected cells as detected by Invader assay. RNAs described in panel A were analyzed by Invader
assay and plotted as relative units. Error bars indicate standard deviations obtained with five to seven animals. (D) Abnormal accumulation of
precursor miRNAs is not detected in AdshAbcc2-infected cells. Buffer (oligo) or liver RNA, as described in panel A, was analyzed by primer
extension with oligonucleotides that hybridize to pre-miR16, pre-miR21, or U6 snRNA (as a loading control).
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the majority of cells. Thus, efficient silencing was not detected
when we used fewer than 2 109 infective units of AdshAbcc2/
mouse (data not shown). These data also show that mouse liver
cells do not support efficient amplification or spread of siRNA
signals, as has been shown in worms or plants (53).
Application of RNAi to gene therapy approaches has first to
face the challenge of avoiding side effects. RNAi-induced tox-
icity has been associated with three major causes: off-target
inhibition, activation of the interferon response, and saturation
of the cellular silencing machinery. Several authors have ques-
tioned the specificity of RNAi, as expression of some nontarget
genes may be decreased (24). We have not conducted detailed
experiments to rule out off-target inhibition in our system.
However, the expression of specific cellular genes such as
that for murine actin was not altered by expression of Abcc2
shRNAs (Fig. 2C and 3D; data not shown). Also, all mice
survived throughout the study and showed normal behavior
without apparent loss of weight or other signs of illness. Liver
functionality was not affected, as ascites, hepatomegaly, hepa-
tocyte necrosis, or liver fibrosis was not apparent after autop-
sies were carried out. In addition, bilirubin levels were not
altered in mice treated with adenovirus expressing siRNAs
other than the specific inhibitors of Abcc2 (Fig. 3E and 4A).
Finally, some sequences of siRNAs and shRNAs or high
doses of these small RNAs can induce the interferon re-
sponse (24, 44). However, we could not detect induction of
the interferon pathway by quantitative RT-PCR of 25oli-
goadenylate synthetase mRNA with RNA isolated from
Hepa 1-6 cells or murine livers infected with AdshAbcc2
(data not shown).
Numerous authors have pointed out the need for more in-
formation about shRNA toxicity by saturation of the cellular
silencing machinery (17, 29, 58). Their worries are based on the
saturability of silencing factors such as Exp-5, Dicer, and RISC
(23, 39, 58). Processing and function of shRNAs require the
cellular silencing machinery. Thus, overexpression of shRNAs
can saturate Exp-5 in tissue culture cells and in vivo (15, 58).
During the process of writing this report, a study was published
showing that high levels of AAV-delivered shRNAs induce
liver injury in mice (15). The authors showed that overex-
pressed shRNAs saturate Exp-5, leading to a decrease in the
accumulation and functionality of liver miRNAs. We hypoth-
esized that a similar result could be obtained with adenovirus-
delivered shRNAs. Besides, adenovirus infection could affect
the silencing machinery by additional mechanisms. On the one
hand, first-generation adenoviruses express VA RNAs that
could saturate Exp-5 (5, 16, 50; data not shown). On the other
hand, VA RNAs can inhibit Dicer function and can be pro-
cessed to functional viral miRNAs that could help in saturation
of the silencing machinery (2, 3, 39, 48). Finally, other adeno-
virus miRNAs could be expressed from other sequences in the
adenovirus genome (2, 3, 39, 48).
To address the saturation of the silencing machinery, we
analyzed the processing and accumulation of cellular miRNAs
in murine livers infected with first-generation adenovirus vec-
tors that express shRNAs. The cellular miRNAs chosen were
let-7, miR16, miR21, and miR122, as they are well expressed in
mouse liver. These miRNAs and their pre-miRNAs were an-
alyzed by Northern blot assay, primer extension, and Invader
(Fig. 5 and data not shown). Even when adenovirus-mediated
shRNA delivery had inhibited the expression of the target gene
for 1 week (from day 5 to day 12, when miRNAs were ana-
lyzed), no differences were observed in the accumulation of
let-7, miR16, and miR21 miRNAs or pre-miRNAs. Also, we
did not observe alterations in the expression of miRNA-regu-
lated genes such as that for Ras, Notch, or RelA (data not
shown). These experiments were performed under conditions
in which more than 95% of the cells were expressing adenovi-
rus-delivered shRNAs. This result indicates that efficient si-
lencing in vivo can be achieved without altering miRNA bio-
genesis or accumulation or the functionality of the RNAi
machinery.
A similar result was described by Grimm et al. when they
used minimal doses of AAV expressing shRNAs (AAV/
shRNA) or, in most cases, when they delivered higher doses of
these vectors but the stem length of the shRNAs was 19 nt.
These conditions are identical to our experimental settings.
However, Grimm et al. also reported that doses of AAV/
shRNA fivefold higher than the dose required for complete
liver transduction (1012 particles of AAV/shRNA) led to tox-
icity in 73% of the animals because of oversaturation of the
cellular miRNA pathway. It would be of interest to analyze if
higher levels of adenovirus expressing shRNAs can also induce
toxicity in our system. To address this question, we have tried
to produce high titers of AdshAbcc2a and -b. However, all of
our attempts ended in production of adenovirus enriched in
infective particles that had lost expression of Abcc2 shRNA,
probably because these sequences have been lost by recombi-
nation (data not shown). Also, in our experiments, doses of
AdGFP or AdWT higher than 4  109 infective units per
mouse led to toxicity that was unrelated to inhibition of the
silencing pathway (data not shown). Therefore, we evaluated
the effect of high levels of adenovirus expressing shRNAs in
293 cells, which allow replication of first-generation adenovirus
vectors. In uninfected cells, the shRNA-mediated inhibition of
a luciferase reporter was fivefold whereas the inhibition
dropped to two- to threefold in cells infected for 3 days with
AdWT, AdGFP, or AdshAbcc2a (data not shown). Similar
results have been obtained by others with AdWT (2, 39). These
results indicate that adenovirus-infected cells may have im-
paired shRNA processing or function. However, in the same
cells we did not detect an alteration of the processing or func-
tion of endogenous miRNAs (data not shown). We believe that
longer times postinfection may be required to affect these
miRNAs. In fact, a decrease in mouse liver miRNAs has only
been detected after 2 weeks of infection with AAV overex-
pressing shRNAs (15).
In summary, we show that adenoviral vectors are suitable for
delivery of shRNAs and allow the silencing of a liver trans-
porter for up to 3 weeks. The silencing of the Abcc2 RNA
correlated with inhibition of the bilirubin export function and
with the presence of high levels of shRNAs expressed from the
adenoviral vectors. Moreover, we showed the existence of a
threshold in the levels of processed antisense shRNA required
for efficient target silencing. Importantly, the data presented
in this work indicate that adenovirus expressing functional
shRNAs may efficiently inhibit target genes without alteration
or saturation of the miRNA silencing machinery.
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